Within the hypertensive-diabetic cohort, CHD patients (n = 97 SGLT2i treated vs. n = 69 controls) showed SGLT2 inhibitors reduced MRV(Venular)C risk (P < 0.001, OR = 0.584) but increased AVR1.5-2.0PD risk (P = 0.003). The gene discussed is SLC5A2; the disease is coronary artery disorder.